Multi-functional Fe3O4@HMPDA@G5-Au core-releasable satellite nano drug carriers for multimodal treatment of tumor cells. (5th December 2022)

• Record Type: Journal Article
• Authors: Li, Haiyang; Lin, Lanlan; Yan, Rui; Chen, Zekun; Wen, Xinyu; Zeng, Xianwu; Tao, Caihong
• Is Part Of: European polymer journal. Volume 181(2022)
• Publication Date: 2022-12-05
• Subjects: Nano drug carriers -- Mesoporous PDA -- Photothermal therapy -- Nucleus-satellite structure; Polymers -- Periodicals; Polymerization -- Periodicals; Polymères -- Périodiques; Polymérisation -- Périodiques; Polymerization; Polymers; Periodicals; Electronic journals; 547.705
• DOI: 10.1016/j.eurpolymj.2022.111647
• Languages: English
• ISSNs: 0014-3057

Abstract

Graphical abstract: We report a route of fabricating a hollow mesoporous nucleus-satellite Fe3 O4 @HMPDA@G5-Au drug delivery nano system, which with a large specific surface area and total pore volumes. The preparation process of the microcapsules was simple, mild and no toxic reagent participating. The average DOX capacity of the obtained nano carriers was up to 473.83 mg/g. The small size G5-Au NPs can be released by shell PDA peeling in acidic tumor environment; it can be used for deep penetrating delivery of drugs. The photothermal effect of PDA and AuNPs was also combined. In addition, it can also promote the decomposition of H2 O2 to produce O2 to a certain extent and avoid tumor hypoxia. The vitro experiments showed that the nano drug carrier has obvious inhibitory effect on tumor cells with little side effects under the multi synergistic therapeutic effect. Scheme 1. Synthetic routes of the preparation of Fe3 O4 @HMPDA@G5-Au@DOX nano drug carrier. Highlights: The two-component photothermal nanocomposite endowed the nano system have high photothermal conversion efficiency (46.53%). The large cavity structure and shell mesoporous structure endowed the carrier greater drug capacity (473.83 mg/g). In acidic tumor environment, small G5 Au NPs can be used for deep penetration drug delivery. It can also promote the decomposition of H2 O2 to produce O2 to a certain extent and avoid tumor hypoxia. The cell experiments showed that the nonosystem had significant inhibition on tumor cells with little side effects. Abstract: Combination therapy has become an effective strategy for tumor treatment, but the preparation of drug nanocarriers with the high requirements still lacked exploration. In this paper, hollow shell-layer mesoporous polydopamine (HMPDA) was constructed on Fe3 O4 nanoparticles (the magnetic core), and small-sized G5-Au nanoparticles (AuNPs) as the releasable satellite carriers for tumor deep treatment were modified on HMPDA surface, then the nucleus-satellite Fe3 O4 @HMPDA@G5-Au nano drug delivery carriers were obtained. The therapy drug could be loaded in the mesoporous structure of HMPDA and G5-Au nanoparticles, so the drug loading capacity was relatively large. The Fe3 O4 @HMPDA@G5-Au composite nano carriers also had good photothermal properties, because polydopamine (PDA) and AuNPs were both good photothermal agents. Combination of photothermal therapy (PTT) and drug therapy could significantly enhance the ablation of tumor cells with minor side effects. In addition, the decomposition of H2 O2 in the tumor site catalyzed by the AuNPs could also produce oxygen to alleviate tumor hypoxia. In addition, because of the magnetic properties of Fe3 O4 nanoparticles, the Fe3 O4 @HMPDA@G5-Au nano drug delivery carriers also had magnetic targeting performance and could reach the specified position under the guidance of external magnetic field. The results showed that the average DOX loaded amount of the prepared carriers was 473.83 mg/g, the drug release rate in 24 h could achieve 61.3 %. The cytotoxicity test showed that the drug loaded carriers had a significant inhibitory effect on HepG2 cells. The drug-loaded core-satellite nanocarriers could play a good synergistic treatment effect on cancer under the multi effect synergy of PPT, drug therapy, magnetic targeting and pH-responsive drug release.